| Trade date | Director | Volume / Price | Trade value | Trade type |
|---|---|---|---|---|
| 05/02/2025 | Nicolas Loebel | 25,000 @ 12.60p | £3,150.00 | Buy |
| 03/02/2025 | Carolyn Cross | 149,225 @ 12.50p | £18,653.13 | Buy |
| 31/01/2025 | Carolyn Cross | 100,000 @ 12.50p | £12,500.00 | Buy |
| 30/01/2025 | Carolyn Cross | 200,775 @ 12.00p | £24,093.00 | Buy |
| Name | Holding | Percent |
|---|---|---|
| Carolyn Cross | 156,314,029 | 35.00% |
| Nicolas Loebel | 3,538,991 | 0.00% |
| Junaid Bajwa | 1,193,697 | 0.00% |
| Jean Duvall | 1,163,529 | 0.00% |
| Michael Farrar | 484,806 | 0.00% |
| Jean Charest | 353,356 | 0.00% |
| Simon Sinclair | 256,327 | 0.00% |
| Institution name | Holding | Percent |
|---|---|---|
| Carolyn Cross | 119,258,222 | 23.01% |
| M&G Plc | 67,254,901 | 12.97% |
| hInsight-NX, LLC | 42,272,654 | 8.15% |
| Robert Cross | 37,772,652 | 7.29% |
| Albemarle Life Sciences Fund | 15,105,882 | 3.83% |
| CRUX Asset Management | 9,298,090 | 4.78% |
| Chelverton Asset Management | 7,957,311 | 4.09% |